Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells

Breast cancer (BC) is associated with type 2 diabetes mellitus (T2DM) and obesity. Glucagon-like peptide (GLP)-1 regulates post-prandial insulin secretion, satiety, and gastric emptying. Several GLP-1 analogs have been FDA-approved for the treatment of T2DM and obesity. Moreover, GLP-1 regulates var...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical oncology (Northwood, London, England) London, England), 2024-05, Vol.41 (6), p.138, Article 138
Hauptverfasser:	Ligumsky, Hagai, Amir, Sharon, Arbel Rubinstein, Tamar, Guion, Kate, Scherf, Tali, Karasik, Avraham, Wolf, Ido, Rubinek, Tami
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenylate Kinase - metabolism AMP-Activated Protein Kinases - metabolism Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Exenatide - pharmacology Female Glucagon Glucagon-Like Peptide 1 - analogs & derivatives Glucagon-Like Peptide 1 - metabolism Glucagon-Like Peptide 1 - pharmacology Hematology Humans Internal Medicine Kinases Liraglutide - pharmacology Medicine Medicine & Public Health Metabolism Metabolites Oncology Original Paper Pathology Peptides Peptides - pharmacology Signal Transduction - drug effects Venoms - pharmacology Warburg Effect, Oncologic - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!